business
Lilly Gets Back Into the Vaccine Business With New Deals
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports. (Source: Bloomberg)
Read full story on Bloomberg Markets → More top storiesAlso covered by
CNBC
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
STAT News
STAT+: Eli Lilly to buy three small vaccine developers
Investing.com
Lilly to acquire three vaccine developers for up to $3.83 billion
STAT News
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop